1. Home
  2. NXGL vs CLGN Comparison

NXGL vs CLGN Comparison

Compare NXGL & CLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NexGel Inc

NXGL

NexGel Inc

HOLD

Current Price

$0.32

Market Cap

4.9M

Sector

Health Care

ML Signal

HOLD

Logo CollPlant Biotechnologies Ltd

CLGN

CollPlant Biotechnologies Ltd

HOLD

Current Price

$3.50

Market Cap

5.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NXGL
CLGN
Founded
1997
2004
Country
United States
Israel
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Industrial Specialties
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.9M
5.2M
IPO Year
2019
2015

Fundamental Metrics

Financial Performance
Metric
NXGL
CLGN
Price
$0.32
$3.50
Analyst Decision
Strong Buy
Buy
Analyst Count
1
2
Target Price
$2.00
$11.00
AVG Volume (30 Days)
562.1K
9.4M
Earning Date
05-11-2026
05-27-2026
Dividend Yield
N/A
N/A
EPS Growth
24.00
N/A
EPS
N/A
N/A
Revenue
$11,421,000.00
N/A
Revenue This Year
$50.77
$240.45
Revenue Next Year
$46.15
$38.03
P/E Ratio
N/A
N/A
Revenue Growth
31.46
N/A
52 Week Low
$0.30
$0.26
52 Week High
$2.89
$3.18

Technical Indicators

Market Signals
Indicator
NXGL
CLGN
Relative Strength Index (RSI) 41.53 52.42
Support Level $0.32 $0.30
Resistance Level $0.61 $0.43
Average True Range (ATR) 0.05 0.09
MACD -0.00 0.01
Stochastic Oscillator 25.14 10.90

Price Performance

Historical Comparison
NXGL
CLGN

About NXGL NexGel Inc

NexGel Inc manufactures high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company specializes in custom gels by capitalizing on proprietary manufacturing technologies. The gels and consumer products are manufactured using proprietary and non-proprietary mixing, coating and cross-linking technologies.

About CLGN CollPlant Biotechnologies Ltd

CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives majority revenue, Canada, Europe and Other, and Israel.

Share on Social Networks: